Cancel
Apollomics
See Linkedin
Apollomics Employees
5 people indexed:
-
Chinglin Lai
Senior Vice President of Biostatistics and Data Management
0z22wdbq.r95@38jjx6xuvvzrk.xrx Sign up to see emailxb8wu5ef.qjk@40735utt0vvr4.zky Sign up to see email -
Guo-Liang Yu
Co-Founder, Executive Director, Chairman and Chief Executive Officer
3h2b98ktf.89@733tvz956ejk1.08b Sign up to see emaile00jjtk93.e4@43qvk3jd31q2b.twt Sign up to see email -
f6rj0z46.vrdj9.4t@1jwxxfjb32011.176 Sign up to see email
-
qj82r18.83jf19gd@db8gd66yjj576.93v Sign up to see email
-
Sanjeev Redkar
Co-Founder, Executive Director and President
g42y4g0.6f42h0@87q6q9xuq4x4t.2yf Sign up to see email03311y5.1wb153@fq00b2w8q84ug.fhg Sign up to see email
Apollomics Company Information
Apollomics is a biopharmaceutical company that specializes in the development of novel oncology therapies aimed at harnessing the immune system and targeting specific molecular pathways to inhibit cancer growth. The company’s extensive pipeline features several targeted therapies such as Vebreltinib (APL-101), Uproleselan (APL-106), APL-102, and APL-501. Vebreltinib is a c-Met inhibitor designed to address dysregulation in multiple tumor types. Uproleselan aims to enhance chemotherapy response rates and improve survival outcomes in patients with hematologic cancers. APL-102 functions as a multi-kinase inhibitor targeting key oncogenic drivers, while APL-501, an anti-PD-1 antibody, is developed to boost the immune response against tumors. Apollomics operates across three major regions: the United States, China, and Australia, focusing on the global development and commercialization of their therapies.
Report inaccurate information
Report inaccurate information
